Vitae Pharmaceuticals, Inc.

Inemsoft, Inc.

Other

Boehringer Ingelheim International Gmbh

Hughes Electronics Corporation

Hughes Network Systems, LLC

Wei Zhao

Suresh B Singh

Colin M Tice

David A Claremon

Linghang Zhuang

Lawrence Wayne Dillard

Jing Yuan

Yi Fan

Stephen D Lotesta

Chengguo Dong

Yajun Zheng

Zhenrong Xu

Salvacion Cacatian

Katerina Leftheris

Lanqi Jia

Yuanjie Ye

Andrew Marcus

Robert Simpson

Gerard McGeehan

John J Baldwin

Alexey V Ishchenko

Patrick Flaherty

Wei He

Todd Lehmann

Allen Nemer

Shaldon Li

Zhijie Liu

Anthony Robert Noerpel

Jean-Pierre Wery

Frank Himmelsbach

Matthias Eckhardt

David Alan Roos

Sheel Agarwal

Mindaugas Rackaitis

Dave Roos

Abheek Saha

Alan J Lesser

Sandeep Verma

Nihal Kanbargi

Tom Peters

Fei Yang

Kennon Cogdell

Steven Arnold

Gerard M Mcgeehan

Patrick T Flaherty

Linghang Zhung

Robert D Simpson

In one embodiment, a method includes receiving a trigger to dynamically modify a serving site of a communication endpoint, wherein the communication endpoint is registered to receive digital communication service from a first serving site. The method further includes determining a stored serving-site selection policy applicable to the communication endpoint. The method also includes selecting a second serving site for the communication endpoint based, at least part, on a stored serving-site selection policy. Also, the method includes determining endpoint-configuration requirements of the second serving site. Furthermore, the method includes dynamically generating endpoint configurations that satisfy the endpoint-configuration requirements of the second serving site. Moreover, the method includes writing the generated endpoint configurations to the communication endpoint. Additionally, the method includes causing the communication endpoint to register to receive digital communication service from the second serving site in place of the first serving site.

Systems and methods of managing communication endpoints

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR&#x3b3;. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders. 

Benzimidazole derivatives as modulators of ROR-gamma

Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR&#x3b3;. Such derivatives include e.g., those having the Formula II:  as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Substituted benzoimidazoles as modulators of ROR-&#x3b3;

Methods are described for treatment of aramid fibers to modify the surface of the fibers. The treated fibers have improved adhesion to elastomer materials as compared to untreated fibers. Modification methods include irradiating the fibers, compressing and straining the fibers under a constant pull force and immersing the fibers in a coupling agent fluid. The treated fibers can be used with elastomers and provide reinforcement elements in products such as tires.

Methods for modification of aramid fibers

A lamp power supply realize 0 percent flicker and 0 flicker index with feedback setting the product of voltage and current of the lamp equal to the reference voltage times a constant.

Lamp power supply with 0 percent flicker and 0 flicker index

Provided are novel compounds of Formula (I):  pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Substituted indoles as modulators of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of Formula (I) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer's disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. 

Piperazine derivatives as liver X receptor modulators

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Dihydropyrrolopyridine inhibitors of ROR&#x3b3;

Growing community of inventors

Eagleville, PA, United States of America

Wei Zhao